IHC Jun 22, 2022 Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review Jun 9, 2022 Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients Jun 8, 2022 Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Jun 6, 2022 Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium Mar 25, 2022 Study Shows TIL-Based Biomarker Could Predict Checkpoint Inhibitor Response in NSCLC Premium Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Mar 3, 2022 Carsgen to Start Phase II Trial of CAR T-Cell Therapy for Advanced Gastric, GEJ Cancer in China Dec 23, 2021 Multiomic Profiling Uncovers Predictors of Melanoma Response to Immunotherapy Oct 5, 2021 Zymeworks, ALX Oncology Dose First HER2-Expressing Cancer Patient in Targeted Combo Trial Aug 20, 2021 Labcorp, CCORN Ink Partnership to Address Precision Oncology Disparities Aug 19, 2021 Mounting Research Backs MHC as Immune Checkpoint Inhibitor Biomarker Premium Jul 30, 2021 Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer Premium Jul 14, 2021 Bayer, OncoDNA, Tamkin Al-Seha Medical Partner to Offer NTRK Fusion Testing in Saudi Arabia Jun 5, 2021 Engineered TCR Therapy Demonstrates Durable Responses in Rare Sarcomas Jun 4, 2021 Akoya Biosciences, AstraZeneca Collaborate on Spatial Biomarker Profiling for Immuno-Oncology May 5, 2021 FDA Approves Keytruda-Herceptin Combination for HER2-Positive Gastric, Gastroesophageal Cancer Apr 23, 2021 Ligand Expression Predicts Vectibix Benefit in Colon Cancer, Roche and U of Leeds Study Says Apr 22, 2021 FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
